We are live on ! Find out more
IRD

Opus Genetics

50 hedge funds and large institutions have $11.3M invested in Opus Genetics in 2023 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,525% more call options, than puts

Call options by funds: $435K | Put options by funds: $12K

44% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 9

2% more funds holding

Funds holding: 4950 (+1)

9% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 11

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

1.22% less ownership

Funds ownership: 17.87%16.65% (-1.2%)

10% less capital invested

Capital invested by funds: $12.6M → $11.3M (-$1.23M)

Holders
50
Holders Change
+1
Holders Change %
+2.04%
% of All Funds
0.73%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
12
Increased
13
Reduced
9
Closed
11
Calls
$435K
Puts
$12K
Net Calls
+$423K
Net Calls Change
+$264K

IRD Hedge Fund Activity: Q4 2023 in Review

50 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q4 2023, worth a combined $11.3M — down 9.8% from $12.6M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new IRD positions and 11 closed out — a net gain of 1 holder — while 13 added to existing stakes and 9 trimmed.

The largest buyer was Bridgeway Capital Management, adding an estimated $390K. The largest seller was Rice Hall James & Associates, cutting an estimated $759K.

  • 50 institutional investors held Opus Genetics (IRD) as of Q4 2023, up from 49 in Q3 2023.
  • Funds reported $11.3M of Opus Genetics stock for Q4 2023, down 9.8% quarter-over-quarter.
  • 12 funds opened new Opus Genetics positions in Q4 2023 and 11 closed out, a net change of +1 holder.
  • The largest Opus Genetics buyer in Q4 2023 was Bridgeway Capital Management, an estimated $390K added.
  • The largest Opus Genetics seller in Q4 2023 was Rice Hall James & Associates, an estimated $759K sold.

Based on aggregated 13F filings for Q4 2023.